Theravance Biopharma Announces First Subject Dosed in Phase 1 Study of TD-0903, in Development for the Treatment of Hospitalized Patients with Acute Lung Injury Caused by COVID-19

Corporate Communications and Investor Relations
917-214-6603 SOURCE Theravance Biopharma, Inc.
